|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||21.95 - 23.24|
|52 Week Range||10.75 - 24.74|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.33|
NEW YORK, Aug. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
WILMINGTON, Del., Aug. 19, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Presidio, Inc. (NASDAQ GS: PSDO) regarding possible breaches of fiduciary.
NEW YORK, NY / ACCESSWIRE / August 16, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Wesco Aircraft Holdings, Inc. (NYSE:WAIR) The investigation ...
NEW YORK, Aug. 15, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Avedro, Inc. to Glaukos Corporation .
WILMINGTON, Del., Aug. 13, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary.
NEW YORK, Aug. 13, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
NEW YORK, Aug. 12, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Avedro, Inc. (NASDAQ: AVDR) to Glaukos Corporation is fair.
Under the terms of the transaction, each share of Genomic common stock will be converted into the right to receive $27.50 in cash and $44.50 in shares of Exact Sciences for each share of Genomic common stock owned. Under the terms of the agreement, each share of Navigant common stock will be converted into the right to receive $28.00 in cash for each share of Navigant common stock owned.
WILMINGTON, DE / ACCESSWIRE / August 9, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Avedro, Inc. (NASDAQ GM: AVDR )? Did you purchase any of your shares prior to August 7, 2019? Do you think the ...
NEW YORK , Aug. 8, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Avedro, Inc. (NASDAQ: AVDR) on behalf of Avedro shareholders concerning ...
NEW YORK, Aug. 08, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Avedro, Inc. (“Avedro” or the.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO ) Allakos Inc (NASDAQ: ...
Updates Full Year 2019 Revenue Guidance Earnings Call and Webcast Previously Scheduled for Tomorrow, Thursday, August 8 Will Now Occur Today, Wednesday, August 7 at 4:30 p.m..
Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement under which Glaukos will acquire Avedro in an all-stock transaction. The transaction, which is subject to Avedro stockholder approval along with other customary closing conditions and regulatory approvals, has been approved by the board of directors of both companies and is expected to be completed in the fourth quarter of 2019. Glaukos plans to leverage its proven market-building expertise, global commercial scale and extensive clinical and regulatory infrastructure to maximize Avedro’s disruptive bio-activated pharmaceuticals and pipeline.
WALTHAM, Mass., July 25, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), today announced that it will release financial results for the second quarter of 2019 after the close.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
WALTHAM, Mass., May 20, 2019 -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), today announced the company will be participating in the upcoming Guggenheim MedTech Disruptors Summit.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $1. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...